CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) attributable to Manhattan Scientifics, Inc.	$ (147,000)	$ (5,337,000)
Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities:
Stock options issued/vested for services		240,000
Depreciation and amortization	609,000	745,000
Treasury stock cancelled and returned to authorized		3,000
Loss from equity-method investments, net	694,000
Adjustment for noncontrolling interest	(2,037,000)
Changes in:
Accounts receivable	44,000	(30,000)
Accounts payable and accrued expenses	229,000	730,000
Deferred revenue		27,000
Net cash provided by/(used in) operating activities	(608,000)	(3,622,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(8,000)	(13,000)
Net cash used in investing activities	(8,000)	(13,000)
NET INCREASE IN CASH AND CASH EQUIVALENTS	(616,000)	(3,635,000)
Cash and cash equivalents, beginning of year	1,068,000	5,364,000
CASH AND CASH EQUIVALENTS, END OF YEAR	452,000	1,729,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid		100,000
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Conversion of debt to preferred stock by shareholder
Loss on forgiveness of debt	(6,739,000)
Gain in change in accounting treatment	$ 8,758,000